26 related articles for article (PubMed ID: 38670561)
1. Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females.
Harper DM; Vierthaler SL
ISRN Obstet Gynecol; 2011; 2011():457204. PubMed ID: 22111017
[TBL] [Abstract][Full Text] [Related]
2. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection.
Choi W; Shim E
Prev Med; 2024 Jan; 178():107743. PubMed ID: 37866695
[TBL] [Abstract][Full Text] [Related]
4. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia.
Wondimu A; Postma MJ; van Hulst M
Vaccine; 2022 Mar; 40(14):2161-2167. PubMed ID: 35248423
[TBL] [Abstract][Full Text] [Related]
6. Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis.
Portnoy A; Pedersen K; Nygård M; Trogstad L; Kim JJ; Burger EA
Med Decis Making; 2022 Aug; 42(6):795-807. PubMed ID: 35255741
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting.
Termrungruanglert W; Khemapech N; Vasuratna A; Havanond P; Tantitamit T
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38670561
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
9. Overview of the benefits and potential issues of the nonavalent HPV vaccine.
Mariani L; Preti M; Cristoforoni P; Stigliano CM; Perino A
Int J Gynaecol Obstet; 2017 Mar; 136(3):258-265. PubMed ID: 28087890
[TBL] [Abstract][Full Text] [Related]
10. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
Zhang Z; Zhang J; Xia N; Zhao Q
Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
[TBL] [Abstract][Full Text] [Related]
11. Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.
Soe NN; Ong JJ; Ma X; Fairley CK; Latt PM; Jing J; Cheng F; Zhang L
Hum Vaccin Immunother; 2018; 14(12):3010-3018. PubMed ID: 30024823
[TBL] [Abstract][Full Text] [Related]
12. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
